Abbott
Cardiovascular

HeartMate 3 LVAD

Clinically proven to disrupt heart failure progression

5+ Year Survival Rates with LVAD

The HeartMate 3™ Left Ventricular Assist Device (LVAD) provides life-prolonging therapy in a patient population who otherwise would not be expected to survive beyond 9 months.1,2

  • Median survival is more than 5 years with HeartMate 3 LVAD1
  • 79% of patients improved NYHA class1
Access Clinical Results Now

Is HeartMate 3 LVAD the right solution for your patients?

Sign up to get the latest clinical advancements, education, and patient resources:

  • Access comprehensive clinical data, trial outcomes and more educational resources for healthcare professionals working in heart failure

Underutilization of HeartMate 3 LVAD in Advanced Heart Failure

In this episode of Between Two Ventricles™ HF Podcast, Michael Zhen-Yu Tong, M.D., MBA, FRCSC, and Dr. Phil Adamson emphasize how median survival with HeartMate 3 LVAD reliably exceeds 5 years, even in those patients with refractory heart failure who are ineligible for transplantation.

Listen to the Podcast

References

  1. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Tria. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197
  2. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8(5):880-886.

Banner 8

Banner 9

Banner 10

Banner 11

MAT-2412503 v1.0